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A report of three casesDear Editor,
Hymenoptera venom allergy is the second cause of anaphylaxis
in European children.1 Systemic reactions occur in up to 0.8% of
schoolchildren.2 Venom immunotherapy (VIT) is recommended in
sensitized children having systemic skin reactions exceeding gener-
alized skin symptoms.3 VIT carries an 8e20% risk of systemic
adverse events.3 Short protocols achieve the maintenance dose
faster than conventional protocols but are more frequently associ-
ated with anaphylactic reactions.3
We report the cases of teenagers who experienced severe
anaphylactic reactions (SAR) during the rush phase of VIT (Table 1).
After an informed consent, a second rush VIT was performed after
a pretreatment with omalizumab and was tolerated. No injection
of omalizumab was required during the maintenance phase.
Case 1. A 15-year-old boy, son of a beekeeper, experienced SAR to
bee stings (urticaria, respiratory distress, hoarse voice, malaise). In-
tradermal (ID) test was positive (5 mm at 0.001 mg/ml), speciﬁc bee
venom IgE level was 2.11 KU/L. The basal serum tryptase (BST) level
was not determined. A ﬁrst four-day rush VIT (Alyostal®, Stallergenes,
Antony, France) was conducted in 2007. The child had a respiratory
distress with generalized urticaria after an injection of 40 mg at day
2. At day 3, an injection of 10 mg was well tolerated, but he relapsed
after an injection of 20 mg, despite a pretreatment with intravenous
dexchlorpheniramine. Four hours later, he tolerated an injection of
10 mg, but relapsed after the injection of 20 mg. A second rush VIT
was proposed in 2008 after a pretreatment with omalizumab
(weight ¼ 56 kg, total serum IgE level ¼ 95 KU/l, dose ¼ 150 mg, 4
and 2 weeks before the onset of VIT). No systemic reactions occurred
during the second VIT, the patient tolerated the target dose of 100 mg.
Themaintenance protocol was performed and tolerated for ﬁve years
(Table 1). At that time, ID were negative, the speciﬁc IgE level was
0.81 KU/L. In 2009, a ﬁeld resting by a bee was tolerated.
Case 2. A 12-year-old boy experienced a SAR (facial angioedema,
respiratory distress) to a wasp sting. ID test was positive for wasp
venom (12 mm at 0.001 mg/ml) and the speciﬁc IgE level was
26.10 KU/L. The BST level was not determined. A ﬁrst four-day
rush VIT (Alyostal®) was conducted in 2008. The patient had
more and more intense and early large local reactions during the
updosing phase, and an anaphylactic shock occurred at day 4,
immediately after the injection of 100 mg, despite pretreatment
with dexchlorpheniramine. A second rush was performed after aPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).pretreatment with omalizumab (weight ¼ 43 kg, total serum IgE
level ¼ 790 KU/l, dose ¼ 300 mg, 4 and 2 weeks earlier). No sys-
temic reaction occurred during the rush, the target dose of
100 mg was achieved. VIT was continued without adverse events
for 5 years. The patient was ﬁeld restung by a wasp without any re-
action in 2009. In 2011, the IDwas positive (10mmat 0.1 mg/ml), the
speciﬁc IgE levels were 3.05 KU/l.
Case 3. A 14-year-old boy, son of a beekeeper, had a SAR to a bee
sting (urticaria, facial angioedema, respiratory distress, dysphagia,
abdominal pain, vomiting). ID test to bee venom was positive
(8 mm at 0.001 mg/ml), speciﬁc IgE levels against bee venom and
Api m 1 were both > 100 KU/L. The BST level was normal (2.7 mg/
l). A ﬁrst rush VIT (Alyostal®) was conducted in 2014, and stopped
at day 2, due to a generalized urticarial with respiratory distress
and stridor occurring after the injection of 40 mg, despite pretreat-
ment with dexchlorpheniramine. A second rush VIT was performed
successfully after a pretreatment with omalizumab (weight ¼
61 kg, total serum IgE level ¼ 305 KU/l, dose ¼ 450 mg, 4 and 2
weeks earlier). The child is currently under maintenance protocol
for 4 years, without any adverse events. In 2016, speciﬁc IgE levels
against bee venom and Api m 1 were 89.2 KU/L and 42.9 KU/L.
In our department, (located in a low risk area of hymenoptera
stings), 90 children were treated with VIT between 1999 and
2016. Five (5.6%) experienced SAR during the rush phase. Two chil-
dren (2/5) (both sons of beekeeper) stopped deﬁnitively the VIT at a
time when omalizumab was not marketed. Case reports suggested
that pretreatment ± cotreatment with omalizumab may prevent
the recurrence of SAR during VIT in adults and children.3e6 Our ob-
servations conﬁrm that a short pretreatment with omalizumab
may be effective in children in this indication.
Risk factors for SAR during VIT include mast cell disease (MCD),
bee venom allergy, rapid dose increase during the updosing phase.3
Neither the speciﬁc IgE levels nor the skin reactivity are good pre-
dictors. The BST was determined in only one child, and despite the
other two did not develop any symptoms of MCD, the diagnosis of
indolent MCD cannot be excluded. Large local reactions during rush
VIT, as in case 2, are not predictive of further systemic reactions
during VIT. The frequency of local and mild systemic reactions is
generally reduced with H1 antihistamines pretreatment; in our
cases, this pretreatment did not prevent the occurrence of SAR.3
Api m 4 sensitization was associated with a higher risk of systemic
reactions during the rush phase of bee VIT.7 This suggests a poten-
tial interest for compound-resolved diagnosis in the evaluation of
patients requiring bee VIT.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Protocol for administration of venom immunotherapy.
Day (D) Vial n Concentration
(mg/ml)
Dose
(ml)
Dose
(mg)
Interval between
injections (mn)
D 1 n 1 0.01 mg/ml 0.1 ml 0.001 90
0.5 ml 0.005
n 2 0.1 mg/ml 0.1 ml 0.01
0.5 ml 0.05
n 3 1 mg/ml 0.1 ml 0.1
0.5 ml 0.5
D 2 n 4 10 mg/ml 0.1 ml 1 90
0.5 ml 5
n 5 100 mg/ml 0.1 ml 10
0.2 ml 20
0.4 ml 40
D 3 n 5 100 mg/ml 0.5 ml 50 120
0.5 ml 50
D 4y n 5 100 mg/ml 1 ml 100
y Then maintenance dose of 100 mg at D11, D25 and D46. Then every 4 weeks
during 1 year and a half, every 5 weeks from year 1.5e3, and every 6 weeks from
year 3e5.
Letter to the Editor / Allergology International 68 (2019) 268e269 269Although omalizumab may improve tolerability of VIT, the
optimal dosing and duration of injections are unknown and vary
among the reported cases.4 Omalizumab is generally administered
during both the rush and the maintenance phases. Recurrences of
SAR under VIT have been reported despite the use of omalizumab.8,9
These observations suggest that omalizumab itself may not induce
long-term tolerance of VIT, but that it may rather decrease the
time to reach the maintenance dose and improve safety, as reported
for oral immunotherapy in patients with food allergy.10 This is sup-
ported by studies showing that omalizumab may rapidly decrease
basophil reactivity, before the onset of an immunotherapy.11
The reasons why most adults require more injections than our
patients remain unclear. Rapid updosing phases seem safer in chil-
dren than in adults, potentially because adults have more frequent
cardiovascular diseases and medication use.12 The absence of a re-
action in the children who were ﬁeld restung provides evidence
that VIT was effective, even after discontinuation of omalizumab.
However, our procedure may not be effective in all children, espe-
cially those with MCD.
In summary, a short pretreatment with omalizumab may
improve the tolerance of a rush VIT in some children with SAR dur-
ing a previous rush. A better recognition of the patients who will
beneﬁt the most of this strategy and the optimal treatment dura-
tion need to be evaluated.
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